# A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

> **NCT05739383** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 14012 (actual)

## Conditions studied

- Primary Prevention of Atherosclerotic Cardiovascular Disease

## Interventions

- **DRUG:** Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL
- **DRUG:** Placebo in 1.5ml

## Key facts

- **NCT ID:** NCT05739383
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-03-09
- **Primary completion:** 2029-04-16
- **Final completion:** 2029-04-16
- **Target enrollment:** 14012 (ACTUAL)
- **Last updated:** 2026-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05739383

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05739383, "A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05739383. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*